Robert Wood Johnson Medical School (RWJMS), Psychiatry

Keyphrases

1. Smokers 100%
2. Parkinson's Disease 98%
3. Schizophrenia 75%
4. Bipolar Disorder 52%
5. Alcohol Use Disorder 45%
6. Randomized Controlled Trial 44%
7. Psychiatric Disorders 39%
8. Mental Health 36%
9. Mental Illness 34%
10. Addiction 32%
11. Tobacco Use 32%
12. Cognitive Behavioral Therapy 32%
13. Primary Care 31%
14. Arylsulfatase A 31%
15. Substance Use Disorder 30%
16. Severe Mental Illness 29%
17. Major Depressive Disorder 29%
18. Cocaine 29%
19. Depression in Parkinson's Disease 28%
20. Smoking Cessation 27%
21. Tobacco Dependence 26%
22. Orexin 25%
23. Depressive Symptoms 25%
24. Tobacco 25%
25. Psychiatrists 23%
26. Quality of Life 23%
27. Affective Disorders 23%
28. Psychopathology 23%
29. Tobacco Treatment 23%
30. Antidepressants 23%
31. Genetic Risk 21%
32. Polygenic Score 21%
33. Nicotine 21%
34. Patients with Parkinson's Disease 21%
35. Alcohol Use 20%
36. Psychiatry 19%
37. Schizophrenia Symptoms 19%
38. Suicide 19%
39. Substance Use 19%
40. United States 19%
41. Hypocretin 18%
42. Quit Smoking 18%
43. Abstinence 18%
44. Psychosis 17%
45. Placebo 17%
46. Tobacco Dependence Treatment 17%
47. Alcoholism 17%
48. Depression Treatment 17%
49. Randomized Clinical Trial 17%
50. Epilepsy 17%
51. Older Adults 17%
52. Parkinson Patients 17%
53. Dopamine 16%
54. Suicide Attempt 16%
55. Depressed Patients 16%
56. Alcohol 16%
57. Motivation 15%
58. Opioids 15%
59. New Jersey 15%
60. Opioid Use Disorder 15%
61. Somatization 15%
62. Schizoaffective Disorder 15%
63. Medically Unexplained Symptoms 15%
64. Somatic Symptoms 15%
65. Polygenic Risk Score 14%
66. Social Support 14%
67. Collaborative Study on the Genetics of Alcoholism 14%
68. Alcohol Dependence 14%
69. Anxiety Disorders 14%
70. Suicidal Behavior 14%
71. Risk Factors 13%
72. Smoking Cessation Intervention 13%
73. Physical Symptoms 13%
74. Illness 13%
75. Genome-wide Association Study 13%
76. Somatization Symptoms 13%
77. Quit Attempts 13%
78. Psychotic Disorders 12%
79. Suicidal Ideation 12%
80. Cocaine Seeking 12%
81. Anxiety Symptoms 12%
82. Substance Abuse 12%
83. Orexin System 12%
84. Antiepileptic Drugs 12%
85. Psychiatric Symptoms 12%
86. Comorbid 12%
87. COVID-19 12%
88. Varenicline 11%
89. African American 11%
90. Treatment as Usual 11%
91. Alcohol Abuse 11%
92. Suicide Risk 11%
93. Mindfulness-based Cognitive Therapy 11%
94. Mental Health Care 11%
95. Healthy Lifestyle Intervention 11%
96. Smoking Prevalence 11%
97. Hispanic 11%
98. High Risk 11%
99. Mental Health Problems 11%
100. Orexin Receptors 11%
101. Pharmacotherapy 11%
102. Cannabis Use 11%
103. Nicotine Replacement Therapy 11%
104. Cigarette 11%
105. Latino 11%
106. Meta-analysis 11%
107. Mental Disorders 10%
108. Drug Use 10%
109. Psychiatric Comorbidity 10%
110. Mexican Americans 10%
111. Sexual Behavior 10%
112. Psychiatric Diagnosis 10%
113. Adverse Effects 10%
114. Tobacco Use Disorder 10%
115. Psychosocial Treatment 10%
116. Disability 10%
117. Immigrants 10%
118. European American 10%
119. Cognitive Impairment 10%
120. Mental Health Services 9%
121. DSM-IV 9%
122. Antiretroviral Adherence 9%
123. Externalizing Behavior 9%
124. Caffeine 9%
125. Comorbidity 9%
126. Metachromatic Leukodystrophy 9%
127. Etiology 9%
128. Behavioral Health 9%
129. Psychiatric Patients 9%
130. Fentanyl 9%
131. Ethical Considerations 9%
132. Nucleus Accumbens 9%
133. Motivational Interviewing 9%
134. Somatoform Disorders 9%
135. Odds Ratio 9%
136. COVID-19 Pandemic 9%
137. Alcohol Problems 9%
138. Emergency Department 8%
139. Sexual Dysfunction 8%
140. Healthcare Professionals 8%
141. Impulsivity 8%
142. Cannabis 8%
143. Movement Disorders 8%
144. HIV Patients 8%
145. Antipsychotics 8%
146. Gabapentin 8%
147. Drug Seeking 8%
148. Erectile Dysfunction 8%
149. Behavioral Economics 8%
150. Confidence Interval 8%
151. Quitline 8%
152. Prelimbic Cortex 8%
153. Attention Deficit Hyperactivity Disorder 8%
154. Non-motor Symptoms 8%
155. Genotype 8%
156. Task Persistence 8%
157. Posttraumatic Stress Disorder 8%
158. Lamotrigine 8%
159. Hamilton Depression Rating Scale (HAM-D) 8%
160. Psychiatric Illness 8%
161. Epidemiology 7%
162. Opioid Overdose 7%
163. Male Rats 7%
164. Well-being 7%
165. Primary Care Patients 7%
166. Cigarette Smoking 7%
167. Hispanic Americans 7%
168. Homeless Veterans 7%
169. Deep Brain Stimulation 7%
170. Genetic Correlation 7%
171. Polymorphism 7%
172. People with Schizophrenia 7%
173. Genetic Variants 7%
174. Methadone Treatment 7%
175. Cognitive-behavioral Treatment 7%
176. Binge Eating 7%
177. Dose Effect 7%
178. Usual Care 7%
179. Insomnia 7%
180. Novelty Seeking 7%
181. Drug Dependence 7%
182. Intervention Group 7%
183. Schizophrenic Patients 7%
184. Clinical Trials 7%
185. College Students 6%
186. Temperament 6%
187. Receptor Antagonist 6%
188. Counseling 6%
189. Current Smokers 6%
190. Atypical Antipsychotics 6%
191. Obsessive-compulsive Disorder 6%
192. Polygenic Risk 6%
193. Modafinil 6%
194. Pathological Gambling 6%
195. Nicotine Dependence 6%
196. Cigarettes per Day 6%
197. Anxiety-depression 6%
198. Treatment Outcome 6%
199. Clinical Practice 6%
200. Patients with Schizophrenia 6%
201. Military Veterans 6%
202. Hypocretin System 6%
203. Psychological Distress 6%
204. Co-occurring Disorders 6%
205. Tiagabine 6%
206. People Living with HIV (PLHIV) 6%
207. Adherence Counselling 6%
208. Executive Function 6%
209. Control Subjects 6%
210. Electroconvulsive Therapy 6%
211. Depressive Disorder 6%
212. Treatment Response 6%
213. Race-ethnicity 6%
214. Genetic Association 6%
215. Personalized Feedback 6%
216. Personality Traits 6%
217. Chronic Fatigue Syndrome 6%
218. Parkinson 6%
219. Personality Disorders 6%
220. HIV-positive 6%
221. Intention to Quit 6%
222. Cortex 6%
223. Diagnostic Criteria 6%
224. High Prevalence 6%
225. Mood Disorders 6%
226. National Guard 6%
227. Receptor Signaling 6%
228. Sleep Quality 6%
229. Treatment Engagement 6%
230. DSM-5 6%
231. SB-334867 6%
232. Comorbid Conditions 6%
233. Physical Health 6%
234. Female Rats 5%
235. Bupropion 5%
236. Cotinine 5%
237. Autism Spectrum Disorder 5%
238. Clinical Outcomes 5%
239. Arylsulfatase 5%
240. Minority Women 5%
241. Hypochondriasis 5%
242. Seizure 5%
243. Weight Control 5%
244. Latino Immigrants 5%
245. Psychopharmacological 5%
246. Mindfulness-based Cancer Recovery 5%
247. Extended Pedigrees 5%
248. Peer Researchers 5%
249. Moderating Role 5%
250. Intergenerational Transmission 5%
251. Risk Behavior 5%
252. Disorders Diagnosis 5%
253. Evidence-based 5%
254. Body Mass Index 5%
255. Medical Students 5%
256. Clinical Setting 5%
257. Sex Differences 5%
258. Persons with Mental Illness 5%
259. Alcoholic 5%
260. Hierarchical Taxonomy of Psychopathology (HiTOP) 5%
261. Reward Seeking 5%
262. Acculturation 5%
263. Haloperidol 5%
264. Substance Abuse Treatment 5%
265. Telephone-based 5%
266. Cognitive Function 5%
267. European Ancestry 5%
268. Genetic Architecture 5%
269. Smoking Status 5%
270. Treatment Programs 5%
271. Amygdala 5%
272. Drugs of Abuse 5%
273. Family Members 5%
274. Self-administration 5%
275. Anticonvulsant 5%
276. Intermittent Access 5%
277. Nicotine Content 5%
278. African Ancestry 5%
279. Heroin 5%
280. Common Variants 5%
281. Impulse Control Disorders 5%
282. Bipolar I Disorder 5%
283. Chronic Pain 5%
284. National Institute of Mental Health 5%
285. Ethical Issues 5%
286. Benzodiazepines 5%
287. Physical Functioning 5%
288. Methadone Clinic 5%
289. Addiction Treatment 5%
290. Carbamazepine 5%
291. Motor Impairment 5%
292. Cardiovascular Risk 5%
293. Posttraumatic Stress Symptoms 5%
294. Insulin 5%
295. Weight Gain 5%
296. Non-Hispanic White 5%
297. Readjustment 5%
298. Self-report Measures 5%
299. Mindfulness 5%
300. Mania 5%